[go: up one dir, main page]

HK1248588A1 - 用於癌症治疗中的天花疫苗 - Google Patents

用於癌症治疗中的天花疫苗 Download PDF

Info

Publication number
HK1248588A1
HK1248588A1 HK18108467.7A HK18108467A HK1248588A1 HK 1248588 A1 HK1248588 A1 HK 1248588A1 HK 18108467 A HK18108467 A HK 18108467A HK 1248588 A1 HK1248588 A1 HK 1248588A1
Authority
HK
Hong Kong
Prior art keywords
cancer treatment
smallpox vaccine
compositions
disclosed
methods
Prior art date
Application number
HK18108467.7A
Other languages
English (en)
Inventor
Aladar Szalay
Boris MINEV
Original Assignee
Calidi Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calidi Biotherapeutics, Inc. filed Critical Calidi Biotherapeutics, Inc.
Publication of HK1248588A1 publication Critical patent/HK1248588A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18108467.7A 2015-08-11 2016-08-11 用於癌症治疗中的天花疫苗 HK1248588A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562203835P 2015-08-11 2015-08-11
US201562203835P 2015-08-11
US201562216292P 2015-09-09 2015-09-09
US201562216292P 2015-09-09
US201662317226P 2016-04-01 2016-04-01
US201662317226P 2016-04-01
PCT/US2016/046647 WO2017027757A2 (en) 2015-08-11 2016-08-11 Smallpox vaccine for cancer treatment

Publications (1)

Publication Number Publication Date
HK1248588A1 true HK1248588A1 (zh) 2018-10-19

Family

ID=56787706

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108467.7A HK1248588A1 (zh) 2015-08-11 2016-08-11 用於癌症治疗中的天花疫苗

Country Status (10)

Country Link
US (5) US10105436B2 (zh)
EP (1) EP3334456A2 (zh)
JP (1) JP6788663B2 (zh)
KR (1) KR102201147B1 (zh)
CN (2) CN108135996B (zh)
CA (1) CA3004891C (zh)
EA (1) EA201800148A1 (zh)
HK (1) HK1248588A1 (zh)
MX (1) MX393612B (zh)
WO (1) WO2017027757A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3003133C (en) 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
EP3334456A2 (en) 2015-08-11 2018-06-20 Stemimmune, Incorporated Smallpox vaccine for use in cancer treatment
SG11201903893PA (en) 2016-11-02 2019-05-30 David Evans Synthetic chimeric poxviruses
KR102776166B1 (ko) 2017-08-07 2025-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 안전한 세포 치료제를 생성하기 위한 플랫폼
CA3083158A1 (en) 2017-11-24 2019-05-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for treating cancers
AR115069A1 (es) 2018-05-02 2020-11-25 David Evans Virus vacuna quimérico sintético
EP3787681A4 (en) * 2018-05-02 2022-01-19 Tonix Pharma Holdings Limited Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
CA3116192C (en) * 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
US20220228128A1 (en) * 2019-05-30 2022-07-21 Immunolux International Corp. Use of poxvirus with autologous induced pluripotent stem cells for vaccination and disease therapy
WO2020247385A1 (en) * 2019-06-03 2020-12-10 Immunolux International Corp. Smallpox vaccine and stem cells for treatment of disease
US11110165B2 (en) 2019-10-10 2021-09-07 Ricardo Rosales Ledezma Therapeutic vaccine for the treatment of papillomavirus lesions
CN116056716B (zh) * 2020-05-15 2025-10-31 首尔大学校产学协力团 利用从脂肪组织分离出来的基质血管组分的树突状细胞的激活功能的免疫反应增强用组合物
CN116635060A (zh) * 2020-10-23 2023-08-22 Sk生物科学株式会社 包含编码外来抗原的遗传物质的用于减小靶组织的尺寸或体积的疫苗组合物或药盒
KR102766523B1 (ko) * 2022-04-22 2025-02-13 에스케이바이오사이언스(주) 타겟 조직의 크기 또는 부피 축소용 조성물 또는 이를 포함하는 키트

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010144A1 (en) 1994-04-29 2002-01-24 Robert Sobol Enhancing the sensitivity of tumor cells to therapies
JP2003514024A (ja) 1999-11-12 2003-04-15 オンコリティクス バイオテク，インコーポレーテッド 細胞増殖性疾患の治療のためのウイルス
SG179291A1 (en) * 2003-06-18 2012-04-27 Genelux Corp Modified recombinant vaccinia viruses and other microorganisms, uses thereof
AU2005303912B2 (en) 2004-11-12 2011-02-17 Bayer Schering Pharma Aktiengesellschaft Recombinant Newcastle Disease Virus
RU2009101783A (ru) 2006-06-21 2010-07-27 Апогеникс Гмбх (De) Дифференциальная экспрессия цитокинов il-4 и/или il-10 в злокачественной опухоли человека
WO2008009115A1 (en) 2006-07-18 2008-01-24 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
US8052968B2 (en) 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US20100183542A1 (en) 2006-10-24 2010-07-22 University Of South Alabama Synergism Between Activated Immune Cells and Conventional Cancer Therapies
US8445275B2 (en) 2007-04-27 2013-05-21 Bavarian Nordic A/S Induction of dendritic cell development with macrophage-colony stimulating factor (M-CSF)
EP2173368A1 (en) 2007-07-18 2010-04-14 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
EP2352526A1 (en) 2008-09-19 2011-08-10 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2758120C (en) 2009-04-13 2014-08-19 Apceth Gmbh & Co. Kg Engineered mesenchymal stem cells and method of using same to treat tumors
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
US20110027239A1 (en) 2009-07-29 2011-02-03 Tissue Genesis, Inc. Adipose-derived stromal cells (asc) as delivery tool for treatment of cancer
WO2011070974A1 (ja) 2009-12-07 2011-06-16 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤
WO2012051210A2 (en) 2010-10-11 2012-04-19 The Administrators Of The Tulane Educational Fund Mesenchymal stem cells and related therapies
CN103491978A (zh) 2010-10-25 2014-01-01 明尼苏达大学评议会 用于治疗成胶质细胞瘤的治疗组合物
EP2764119A2 (en) * 2011-10-05 2014-08-13 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US10238698B2 (en) 2012-01-25 2019-03-26 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
KR20170039774A (ko) 2012-07-30 2017-04-11 알렉스 와 힌 영 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
WO2014066834A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
CA2905272A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
WO2015089280A1 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
PT3169341T (pt) 2014-07-16 2019-09-09 Transgene Sa Vírus oncolítico para a expressão de moduladores de pontos de controlo imunitário
CA3003133C (en) 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
AU2016232863A1 (en) 2015-03-18 2017-11-09 StemImmune, Incorporated Virotherapy with an antibody combination
EP3334456A2 (en) 2015-08-11 2018-06-20 Stemimmune, Incorporated Smallpox vaccine for use in cancer treatment
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
KR20240060879A (ko) 2018-06-04 2024-05-08 카리디 바이오테라퓨틱스, 인크. 바이러스 치료법의 강화를 위한 세포-기반 비히클
CA3116192C (en) 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
WO2020247385A1 (en) 2019-06-03 2020-12-10 Immunolux International Corp. Smallpox vaccine and stem cells for treatment of disease

Also Published As

Publication number Publication date
US20210046178A1 (en) 2021-02-18
US20230173062A1 (en) 2023-06-08
CA3004891A1 (en) 2017-02-16
CN108135996B (zh) 2022-06-21
KR102201147B1 (ko) 2021-01-11
WO2017027757A2 (en) 2017-02-16
CN115212301A (zh) 2022-10-21
EP3334456A2 (en) 2018-06-20
US10105436B2 (en) 2018-10-23
EA201800148A1 (ru) 2019-01-31
MX2018001755A (es) 2018-08-01
JP6788663B2 (ja) 2020-11-25
JP2018527344A (ja) 2018-09-20
US12036278B2 (en) 2024-07-16
CN108135996A (zh) 2018-06-08
KR20180042284A (ko) 2018-04-25
US10857225B2 (en) 2020-12-08
US20240335530A1 (en) 2024-10-10
US20180326048A1 (en) 2018-11-15
CA3004891C (en) 2020-04-14
MX393612B (es) 2025-03-24
US20170043010A1 (en) 2017-02-16
US11607450B2 (en) 2023-03-21
WO2017027757A3 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
HK1248588A1 (zh) 用於癌症治疗中的天花疫苗
IL297418B1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
ZA202004557B (en) Modulatory polynucleotides
IL272740A (en) Combined immunotherapy and cytokine control therapy for cancer treatment
IL261008B1 (en) Combined immunotherapy and cytokine control therapy for cancer treatment
MX2023010042A (es) Polinucleotidos moduladores.
IL251435A0 (en) Preparations and methods of use for increased immune response and cancer treatment
MX389560B (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
WO2015168379A3 (en) Combination vaccine devices and methods of killing cancer cells
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
IL254103A0 (en) Compositions and methods for increasing the effectiveness of cancer treatment
EP3518955A4 (en) TERT-IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT THEREOF
MX2017002489A (es) Agentes terapeuticos humanos.
IL275517A (en) Combined methods and treatment of cancer
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
TW201713323A (en) Therapeutic compositions and methods of use thereof
EP3169333A4 (en) Methods and compositions for enhancing cancer therapy
EP3120852A4 (en) Prophylactic and/or therapeutic agent for immune diseases
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
IL258701A (en) Preparations and methods for curing cancer with immune support
WO2016077580A3 (en) Compositions and methods for treating melanoma
IL274866A (en) Preparations and methods for the treatment of cancer
HK1237265A1 (zh) 用於治疗癌症的联合治疗组合物和联合治疗方法
HK40031578A (zh) 用於治疗与癌症、炎症或免疫反应相关的疾病的方法和组合物
HK1240942A1 (zh) 用於增强的免疫应答和癌症治疗的组合物和方法

Legal Events

Date Code Title Description
CHRG Changes in the register